The US FDA has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Researchers discovered that xanomeline-trospium, a new-generation antipsychotic devoid of D2 dopamine receptor blocking ...